CLINICAL OBSERVATION ON PROGNOSIS SURVIVAL RATE AND SIDE EFFECTS OF SEQUENTIAL RADIOTHERAPY AND CHEMOTHERAPY IN PATIENTS WITH STAGE II-III GASTRIC CANCER

被引:2
|
作者
Wang, Shumin [1 ]
Ping, Mei [1 ]
Zhang, Gehong [1 ]
Guo, Yarong [1 ]
Li, Yuanfei [1 ]
Jia, Junmei [1 ]
机构
[1] Shanxi Med Univ, Hosp 1, Dept Oncol, Taiyuan 030001, Peoples R China
来源
ACTA MEDICA MEDITERRANEA | 2021年 / 37卷 / 02期
关键词
Stage II-III; gastric cancer; sequential chemoradiotherapy; prognostic survival rate; toxic and side effects;
D O I
10.19193/0393-6384_2021_2_137
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To investigate the prognosis survival rate of patients with stage II-III gastric cancer treated by sequential radiotherapy and chemotherapy, and the clinical observation of the side effects of radiotherapy and chemotherapy. Methods: A total of 126 patients with stage II - III gastric cancer from April 2014 to August 2016 were randomly selected and randomly divided into a study group and control group according to the random number table method, with 63 patients in each group. The patients in the study group were treated with sequential radiotherapy (chemotherapy radiotherapy chemotherapy), whereas the patients in the control group were treated with simple chemotherapy. The clinical data, recurrence rate, distant metastasis rate, prognosis survival rate and the occurrence of side effects were compared between the study group and the control group. Results: there was no significant difference in age, gender, TNM stage and differentiation between the study group and the control group (P>0.05). Compared with the control group, the recurrence rate of patients in the study group was significantly lower, the overall prognostic survival rate was significantly higher (P < 0.05) and the distant metastasis rate had no significant difference (P > 0.05). There was no significant difference between the two groups (P > 0.05). The overall prognosis survival rate was significantly higher in the study group than in the control group. Compared with the control group, the patients in the study group had decreased nausea, vomiting, oral mucositis, appetite decline, leucopoenia, thrombocytopenia, etc., but there was no significant difference between the two groups (P > 0.05). The incidence of liver and kidney dysfunction and diarrhoea in the study group was significantly lower than that in the control group (P<0.05). Conclusion: The prognosis survival rate of patients with stage II-III gastric cancer undergoing sequential chemoradiotherapy is significantly higher than that of chemotherapy alone. However, in terms of the toxic and side effects of radiochemotherapy, sequential radiochemotherapy is safer.
引用
收藏
页码:903 / 907
页数:5
相关论文
共 50 条
  • [31] Feasibility and outcomes of concurrent paclitaxel chemotherapy and radiotherapy for node-positive stage II-III breast cancer
    Chen, W. C.
    Kim, J.
    Kim, E.
    Silverman, P.
    Overmoyer, B.
    Cooper, B. W.
    Anthony, S.
    Shenk, R.
    Leeming, R.
    Lyons, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S169 - S169
  • [32] Glycemic Variability in Patients With Stage II-III Colon Cancer Treated With Surgery and Adjuvant Chemotherapy
    Mandolfo, Natalie Rasmussen
    Berger, Ann M.
    Struwe, Leeza A.
    Shade, Marcia Y.
    Goldner, Whitney
    Klute, Kelsey
    Langenfeld, Sean J.
    Hammer, Marilyn J.
    ONCOLOGY NURSING FORUM, 2022, 49 (06) : 571 - 584
  • [33] Combined multiagent chemotherapy and radiotherapy is associated with prolonged overall survival in patients with non-operatively managed stage II-III pancreatic adenocarcinoma
    Sugumar, Kavin
    Hue, Jonathan J.
    Hardacre, Jeffrey M.
    Ammori, John B.
    Rothermel, Luke D.
    Dorth, Jennifer
    Saltzman, Joel
    Mohamed, Amr
    Selfridge, Jennifer E.
    Bajor, David
    Winter, Jordan M.
    Ocuin, Lee M.
    HPB, 2022, 24 (04) : 433 - 442
  • [34] Systemic prognostic score and nomogram based on inflammatory, nutritional and tumor markers predict cancer-specific survival in stage II-III gastric cancer patients with adjuvant chemotherapy
    Liu, Xuechao
    Wu, Zhiming
    Lin, Enzi
    Li, Wei
    Chen, Yingbo
    Sun, Xiaowei
    Zhou, Zhiwei
    CLINICAL NUTRITION, 2019, 38 (04) : 1853 - 1860
  • [35] Wnt5a expression and prognosis in stage II-III colon cancer
    Lund, Cecilia Margareta
    Dyhl-Polk, Anne
    Nielsen, Dorte Lisbeth
    Riis, Lene Buhl
    TRANSLATIONAL ONCOLOGY, 2021, 14 (01):
  • [36] P53 EXPRESSION IS A SIGNIFICANT PREDICTOR OF RESPONSE AND PROGNOSIS IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY
    Guarneri, V.
    Piacentini, F.
    Barbieri, E.
    Frassoldati, A.
    Ficarra, G.
    D'Amico, R.
    Conte, P. F.
    ANNALS OF ONCOLOGY, 2009, 20 : 48 - 48
  • [37] Efficacy of consolidation chemotherapy for clinical responder to concurrent chemoradiation in stage II-III squamous cancer of the esophagus
    Chen, Y.
    Wang, J.
    Cheng, X.
    Wang, Q.
    Zhang, Y.
    Wang, W.
    Wu, X.
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] Neoadjuvant trastuzumab in a sequential nonanthracycline-based regimen for patients with stage II-III breast cancer
    Carillio, G.
    Aiello, R.
    Ali, M.
    Mazzola, A.
    Scandurra, G.
    Taibi, E.
    Chiarenza, M.
    Fallica, G.
    Caruso, F.
    Caruso, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [39] The impact of the preoperative waiting period on the survival in patients with clinical stage II / III gastric cancer.
    Kenichiro, Furukawa
    Makuuchi, Rie
    Fujiya, Keiichi
    Nishiwaki, Noriyuki
    Omori, Hayato
    Kaji, Sanae
    Tanizawa, Yutaka
    Bando, Etsuro
    Kawamura, Taiichi
    Koseki, Yusuke
    Asaoka, Raito
    Nakamura, Kenichi
    Waki, Yuhei
    Irino, Tomoyuki
    Terashima, Masanori
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [40] Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer
    Cho, Jang Ho
    Lim, Jae Yun
    Cho, Jae Yong
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (41) : 7407 - 7414